Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
29
BRZE Quote, Financials, Valuation and Earnings
Last price:
$28.26
Seasonality move
:
-9.99%
Day range:
$27.21 - $28.28
52-week range:
$25.22 - $48.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.69x
P/B ratio:
6.29x
Volume:
1.7M
Avg. volume:
2M
1-year change:
-31.77%
Market cap:
$3B
Revenue:
$593.4M
EPS (TTM):
-$1.01
Analysts' Opinion
-
Consensus RatingBraze has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $45.00, Braze has an estimated upside of 59.35% from its current price of $28.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $38.00 representing 100% downside risk from its current price of $28.24.
Fair Value
-
According to the consensus of 12 analysts, Braze has 59.35% upside to fair value with a price target of $45.00 per share.
BRZE vs. S&P 500
-
Over the past 5 trading days, Braze has overperformed the S&P 500 by 0.61% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Braze does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Braze has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Braze reported revenues of $162.1M.
Earnings Growth
-
Braze has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Braze reported earnings per share of -$0.34.
Enterprise value:
2.4B
EV / Invested capital:
5.15x
Price / LTM sales:
4.69x
EV / EBIT:
--
EV / Revenue:
3.94x
PEG ratio (5yr expected):
--
EV / Free cash flow:
78.65x
Price / Operating cash flow:
93.59x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$430.5M
Return On Assets:
-12.24%
Net Income Margin (TTM):
-16.76%
Return On Equity:
-22.62%
Return On Invested Capital:
-22.62%
Operating Margin:
-24.82%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-30 | 2024-04-30 | 2025-04-30 | 2024-04-30 | 2025-04-30 | |
| Income Statement | ||||||
| Revenue | $379.7M | $505.5M | $620M | $135.5M | $162.1M | |
| Gross Profit | $257.1M | $346.1M | $430.5M | $90.9M | $111.2M | |
| Operating Income | -$150.4M | -$142.9M | -$122.3M | -$40.1M | -$40.2M | |
| EBITDA | -$145.2M | -$135.3M | -$111.7M | -$38M | -$37.6M | |
| Diluted EPS | -$1.45 | -$1.28 | -$1.01 | -$0.35 | -$0.34 | |
| Period Ending | 2021-04-30 | 2022-04-30 | 2023-04-30 | 2024-04-30 | 2025-04-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $598.8M | $598.1M | $598.9M | $659.1M | |
| Total Assets | -- | $716.3M | $721.3M | $816.1M | $889.1M | |
| Current Liabilities | -- | $181M | $245M | $305.6M | $343.9M | |
| Total Liabilities | -- | $228.8M | $285.1M | $379.9M | $414.7M | |
| Total Equity | -- | $487.5M | $436.2M | $436.2M | $474.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-30 | 2024-04-30 | 2025-04-30 | 2024-04-30 | 2025-04-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.7M | $3.7M | $41.4M | $19.4M | $24.1M | |
| Cash From Investing | $33.6M | -$54.9M | $97M | -$10.6M | $122.8M | |
| Cash From Financing | $10.9M | $9M | $14.2M | -$1.9M | $605K | |
| Free Cash Flow | -$33M | -$16.7M | $31.1M | $11.4M | $22.9M | |
BRZE
Sector
Market Cap
$3B
$83.1M
Price % of 52-Week High
58.43%
65.26%
Dividend Yield
0%
0%
Shareholder Yield
--
0.68%
1-Year Price Total Return
-31.77%
-12.52%
Beta (5-Year)
--
0.816
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$27.61
200-day SMA
Sell
Level
$35.48
Bollinger Bands (100)
Sell
Level
28.45 - 36.21
Chaikin Money Flow
Buy
Level
17M
20-day SMA
Buy
Level
$27.39
Relative Strength Index (RSI14)
Sell
Level
48.17
ADX Line
Sell
Level
30.7
Williams %R
Neutral
Level
-32.2695
50-day SMA
Sell
Level
$31.12
MACD (12, 26)
Sell
Level
-0.82
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Sell
Level
-1.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9529)
Sell
CA Score
(Annual)
Level (-0.6298)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (0.7992)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.
Stock Forecast FAQ
In the current month, BRZE has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BRZE average analyst price target in the past 3 months is $45.00.
-
Where Will Braze Stock Be In 1 Year?
According to analysts, the consensus estimate is that Braze share price will rise to $45.00 per share over the next 12 months.
-
What Do Analysts Say About Braze?
Analysts are divided on their view about Braze share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Braze is a Sell and believe this share price will drop from its current level to $38.00.
-
What Is Braze's Price Target?
The price target for Braze over the next 1-year time period is forecast to be $45.00 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BRZE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Braze is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BRZE?
You can purchase shares of Braze via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Braze shares.
-
What Is The Braze Share Price Today?
Braze was last trading at $28.26 per share. This represents the most recent stock quote for Braze. Yesterday, Braze closed at $28.24 per share.
-
How To Buy Braze Stock Online?
In order to purchase Braze stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
